Canalicular stenosis as the underlying mechanism for epiphora in patients receiving weekly docetaxel

Oncologist

Volumn 6, Issue 6, 2001, Pages 551-552

  Esmaeli, Bita ^a   Hortobagyi, Gabriel N ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; TAXANE DERIVATIVE;

BREAST METASTASIS; CANCER CHEMOTHERAPY; DACRYOCYSTORHINOSTOMY; DOSE TIME EFFECT RELATION; EARLY DIAGNOSIS; EPIPHORA; HUMAN; LACRIMAL DUCT OCCLUSION; LETTER; PRIORITY JOURNAL; SCREENING; STENT; VISUAL IMPAIRMENT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; LACRIMAL APPARATUS DISEASES; LACRIMAL DUCT OBSTRUCTION; PACLITAXEL;

EID: 0035217465     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-6-551     Document Type: Letter

References (6)

1. Weekly docetaxel in breast cancer: Applying clinical data to patient therapy
2. Docetaxel administered on a weekly basis for metastatic breast cancer
3. Canalicular stenosis secondary to docetaxel (taxotere): A newly recognized side effect
4. Canalicular stenosis secondary to weekly versus every-three-weeks docetaxel in patients with metastatic breast cancer
5. Surgical treatment of canalicular stenosis in patients receiving weekly docetaxel
6. Canalicular stenosis secondary to weekly docetaxel: A potentially preventable side effect